Reply to D. Herchenhorn et al

Targeting Epidermal Growth Factor Receptor to Optimize Chemoradiotherapy in Locally Advanced Head and Neck Cancer: Has Biology Been Taken Into Account?

(2011) Daniel Herchenhorn et al.   JOURNAL OF CLINICAL ONCOLOGY

New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors

(2010) L. F. Chen et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

(2010) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma

(2010) Hiromitsu Hatakeyama et al.   PLoS One

Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines

(2009) Y. Haddad et al.   CLINICAL CANCER RESEARCH

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2009) J. Simon W. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

(2009) Ezra EW Cohen et al.   LANCET ONCOLOGY

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels

(2008) J. K. Salama et al.   ANNALS OF ONCOLOGY

FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

(2008) Rodney J. Taylor et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE